Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease
Abstract
Introduction Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver disease that ranges from hepatic steatosis to non-alcoholic steatohepatitis. Obesity and diabetes mellitus are the prime risk factors for NAFLD. The aim of this study was to find out the prevalence of NAFLD among patients with type 2 diabetes mellitus and to detect the association of NAFLD with cardiovascular disease in them. Study design Prospective observational study. Material and methods The study was conducted on 300 patients with type 2 diabetes mellitus attending the outpatient department of a tertiary care teaching hospital. All patients underwent hepatic ultrasonography to look for hepatic steatosis. Among the 300 patients, 124 were divided into NAFLD and non-NAFLD groups based on the ultrasound findings. These patients were subjected to electrocardiogram, 2D echocardiogram, carotid intima media thickness (CIMT) measurement and ankle brachial pressure index measurement along with measurement of markers of oxidative stress. Results Hepatic steatosis was present in 61% of diabetic patients in this study. Cardiovascular disease was not found to be significantly associated in diabetic patients with NAFLD. However, cardiovascular risk factors like CIMT, high sensitivity c-reactive protein (hs-CRP) and malondialdehyde (MDA) were elevated in these patients. hs-CRP and MDA levels were found to be significantly associated with the severity of NAFLD. Conclusion There is a high prevalenc…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Serum MDA levels are higher in T2D patients with NAFLD (n = 73) than in T2D patients without NAFLD (n = 51), as measured by TBARS assay.
“| T2D and NAFLD | Serum | T2D patients with (n = 73) and w/o NAFLD (n = 51) | TBARS assay | Higher MDA levels in T2D patients with NAFLD | [241] |”
From Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases (2021) · cites this paper as [241]
Cited by
Sorted by citations
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380 · see citing works
Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases
Kehm, R., Baldensperger, T., Raupbach, J., & Höhn, A. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101901 · Cited by 348 · see citing works
“assay Higher MDA levels in T2D patients with NAFLD [241]”
Method
- Authors
- Vanjiappan, S., Hamide, A., Ananthakrishnan, R., Periyasamy, S. G., & Mehalingam, V.
- Affiliations
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
- Corresponding author
- Mehalingam, Vadivelan
- Venue
- Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 12
- Issue
- 4
- Pages
- 479-482
- ISSN
- 1871-4021 (ISSN-L)
- OpenAlex
- W2791724547
- Cited by
- 45
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 10 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 7 · 2019: 2 · 2018: 1
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes & Metabolic Syndrome Clinical Research & Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, hepatic steatosis, cardiovascular disease, carotid intima-media thickness, ankle-brachial index, high-sensitivity C-reactive protein, malondialdehyde, oxidative stress, NAFLD severity, prevalence
- MeSH terms
- C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, India, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Ultrasonography, Biomarkers, Prevalence, Carotid Intima-Media Thickness, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review